Larazotide vs Oxytocin
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Larazotide
Larazotide (AT-1001) is a synthetic octapeptide that acts as a tight junction regulator — it competitively blocks zonulin, the primary physiological driver of intestinal permeability ('leaky gut'). It is one of the few compounds studied in human clinical trials specifically for tight junction dysfunction, with Phase 2 data in celiac disease demonstrating reduced intestinal permeability and symptom improvement even in the presence of ongoing gluten exposure.
Full profileOxytocin
Endogenous 9-amino acid neuropeptide produced in the hypothalamus with roles in social bonding, trust, and childbirth. Research applications span wound healing, anti-inflammatory effects, sexual function, anxiety reduction, and autonomic nervous system regulation. Intranasal administration crosses the blood-brain barrier and is the primary research route for behavioral and neurological applications.
Full profile| Larazotide | Oxytocin | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Larazotide acetate, AT-1001, INN-202 | OT, Pitocin, Syntocinon, trust hormone, bonding peptide |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 0.25mg–1mg mg, 3x daily (before meals) | 10–20IU–100–160IU IU, Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols |
| Administration | Oral (capsule), Subcutaneous injection (research use) | Intranasal spray, Subcutaneous injection, Intravenous (clinical) |
| Key side effects | Headache (most commonly reported adverse event in trials), Nausea (mild), Generally well-tolerated — adverse event rate similar to placebo in clinical trials | Nausea, Headache, Transient hypotension, Hyponatremia (high IV doses — water retention effect) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: Larazotide is fda-approved, while Oxytocin is research-stage.
- Administration: Larazotide — Oral (capsule), Subcutaneous injection (research use); Oxytocin — Intranasal spray, Subcutaneous injection, Intravenous (clinical).
- Dosing units differ: Larazotide is dosed in mg, Oxytocin in IU — they operate at different scales.
- Frequency: Larazotide is typically 3x daily (before meals); Oxytocin is Intranasal 30–60 minutes pre-activity; 1–2x daily for wound healing or anti-inflammatory protocols.
- Research depth: this profile cites 3 sources for Larazotide vs 2 for Oxytocin.
How each works
Larazotide
Zonulin upregulation disrupts the tight junction proteins occludin and claudin, allowing paracellular passage of antigens, LPS, and inflammatory triggers into systemic circulation. Larazotide acts as a tight junction agonist by competitively displacing zonulin from its receptor and directly stabilizing tight junction complexes. The Phase 2b CeD trial (N=342) showed larazotide reduced the ratio of lactulose/mannitol (L/M ratio, standard intestinal permeability marker) and improved GI symptom scores versus placebo in actively-challenged celiac patients.
Oxytocin
Oxytocin binds oxytocin receptors (OTR) throughout the brain and periphery, producing prosocial, anxiolytic, and anti-inflammatory effects. The landmark 2005 Kosfeld et al. Nature study demonstrated that intranasal oxytocin increased trust in humans in economic game paradigms. Peripheral effects include acceleration of wound healing, modulation of inflammatory cytokines, and parasympathetic nervous system activation.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.